Several studies presented at the 54th Annual Meeting of the American Society of Hematology (ASH) found that a regimen that combines bendamustine with rituximab (B-R) may result in superior outcomes compared with the current standard of care, rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (R-CHOP) or rituximab plus cyclophosphamide/vincristine/prednisone (R-CVP), in patients with non-Hodgkin lymphoma (NHL) and mantle cell lymphoma (MCL).
A wealth of abstracts were presented at the 54th Annual Meeting of the American Society of Hematology (ASH), held in Atlanta, Georgia, on December 8-11, 2012. More than 18,000 hematologists and other healthcare professionals from around the world gathered to discuss the latest clinical developments in research, therapies, and practice strategies. Below are some of the highlights from that meeting.
For preventing bone metastases in women with early breast cancer, the current body of evidence does not support the use of osteoclast-targeting agents, ie, bisphosphonates, according to Julie Gralow, MD, director of Breast Medical Oncology at the Fred Hutchinson Cancer Research Center in Seattle, Washington.